Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: Results From a Randomized, Placebo‐Controlled Phase 3 Study
IV secukinumab led to rapid and sustained improvements in clinical measures of PsA, and the safety profile was consistent with that of secukinumab administered subcutaneously.
Authors
- Sarah Whelan (ORCID: https://orcid.org/0000-0003-3468-7405)
- Alexander Torres
- Thomas Dumortier (ORCID: https://orcid.org/0000-0003-4645-4908)
- Liliana Šedová (ORCID: https://orcid.org/0000-0002-2044-3381)
- Guillermo J. Valenzuela (ORCID: https://orcid.org/0000-0003-1552-8812)
- Melvin Churchill (ORCID: https://orcid.org/0000-0001-8347-185X)
- Luminita Pricop
- Alan Kivitz (ORCID: https://orcid.org/0000-0002-1045-1310)
- Xuan Zhu (ORCID: https://orcid.org/0000-0002-8422-2828)
- Atul Singhal
- Ruvie Martin
- Roshan Kotha
Institutions
- University of Nebraska–Lincoln (US)
- Novartis (Switzerland) (CH)
- Charles University (CZ)
- Sharp Grossmont Hospital (US)
- Altoona Center for Clinical Research (US)
- Novartis (United States) (US)
- Novartis (Ireland) (IE)
- Dermatology Specialists (US)
- Center for Rheumatology (US)
Publication Details
- Journal
- Arthritis & Rheumatology
- Published
- 2024-09-19
- DOI
- https://doi.org/10.1002/art.42997
- Citations
- 4
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.88
Funders
- Novartis Pharmaceuticals Corporation